Travere Therapeutics officer plans $303K share sale
The remarks describe the transaction as a required tax-withholding sale under Travere's equity incentive plans, rather than a discretionary trade.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Travere Therapeutics, Inc. (TVTX) officer Peter Heerma reported a proposed sale of 7,215 common shares, with an approximate sale date of April 14, 2026 and an aggregate market value of $302,515.98.
The shares were acquired through performance restricted stock unit vesting on April 13, 2026, as compensation. The remarks state that the sale is mandated by Travere's equity incentive plans to cover tax withholding through a brokerage firm designated by the issuer, and is not discretionary. The form also reports that Peter Heerma sold 7,310 shares on February 3, 2026, for gross proceeds of $234,799.04.
Key Figures
Key Terms
Performance Restricted Stock Unit Vesting financial
sell to cover financial
tax withholding obligation financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.